Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NP-G2-044 + unspecified PD-L1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NP-G2-044 | NP G2 044 | NP-G2-044 is a small molecule that inhibits fascin, resulting in aberrant actin cytoskeleton reorganization, and potentially resulting in decreased tumor cell migration and metastasis (PMID: 27071719). | ||
| unspecified PD-L1 antibody | Experimental PD-L1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05023486 | Phase Ib/II | NP-G2-044 NP-G2-044 + unspecified PD-L1 antibody | NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |